- Molecular NameNomifensine
- Synonym(+-)-nomifensin; (+-)-nomifensine; (+)-nomifensine; (+)-nomiphensine; (R)-1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisochinolin; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinoline; 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline; Nomifensin; Nomifensina [inn-spanish]; Nomifensine hydrogen maleate; Nomifensine maleate; Nomifensinum [inn-latin]
- Weight238.334
- Drugbank_IDN/A
- ACS_NO24526-64-5
- Show 3D model
- LogP (experiment)2.4
- LogP (predicted, AB/LogP v2.0)2.84
- pkaN/A
- LogD (pH=7, predicted)2.43
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.51
- LogSw (predicted, AB/LogsW2.0)0.25
- Sw (mg/ml) (predicted, ACD/Labs)0.7
- No.of HBond Donors2
- No.of HBond Acceptors2
- No.of Rotatable Bonds1
- TPSA29.26
- StatusUS withdrawn
- AdministrationN/A
- PharmacologyA norepinephrine-dopamine reuptake inhibitor test-marketed in the United States by Hoechst AG (now Sanofi-Aventis) that increases the amount of synaptic dopamine available to receptors by blocking dopamine's re-uptake transporter.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability27.0
- Protein binding67.5
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmN/A
- Half life1.5~4 h, prolonged in severe renal impairment.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)LD50=336